Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis.
Steven A MullerBelén Peiró-AventinGiulia BiagioniGiacomo TiniGiulia SaturiChristina KronbergerAnouk AchtenStephan DobnerWouter P Te RijdtAlessio GasperettiAnneline S J M Te RieleGuerino G VarràAlberto PonzianiAlexander HirschAldostefano PorcariManon G van der MeerMattia ZampieriPim van der HarstAndreas KammerlanderElena BiaginiJ Peter van TintelenEmanuele BarbatoFolkert W AsselbergsSilvia MenaleChristoph GräniMarco MerloMichelle MichelsChristian KnackstedtChristian NitscheSimone LonghiBeatrice MusumeciFrancesco CappelliPablo Garcia-PaviaMarish I F J OerlemansPublished in: European journal of heart failure (2024)
Screening according to the 2021 ESC position statement performs well in daily clinical practice. Clinicians should adhere to repeating bone scintigraphy after 3 years, as progressing to ATTRv-CM without signs of ATTRv-CM on first-line diagnostic tests or symptoms is common.